Hp 129Xenon ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 228 | Bronchiolitis obliterans | 1 |
228. Bronchiolitis obliterans
Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03603899 (ClinicalTrials.gov) | September 9, 2020 | 4/10/2017 | Hp129 Xenon Imaging and BOS in Lung Transplantation | Imaging and Understanding Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation With Hyperpolarized 129Xenon MR Lung Imaging | Bronchiolitis Obliterans | Drug: Hp 129Xenon | Children's Hospital Medical Center, Cincinnati | NULL | Recruiting | 6 Years | N/A | All | 45 | Phase 1/Phase 2 | United States |